Previous 10 | Next 10 |
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported important progress related to the regulator...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,250 restricted stock units o...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2023-08-21 09:02:22 ET Summary ATRA is going to report topline results of a double-blind, randomized, placebo-controlled phase 2 study in progressive multiple sclerosis in November. Based on strong pathophysiological rationale and very promising early-phase data, including support...
2023-08-16 03:00:21 ET Summary Baupost Group's 13F portfolio value decreased from $5.85B to $5.61B this quarter. The portfolio is heavily concentrated, with Liberty Global, Liberty Media Sirius XM, ViaSat, Alphabet, and Veritiv accounting for approximately 58% of the holdings. ...
2023-08-08 16:21:06 ET Atara Biotherapeutics press release ( NASDAQ: ATRA ): Q2 GAAP EPS of -$0.68 misses by $0.01 . Revenue of $0.96M (-98.1% Y/Y) misses by $2.81M . Cash, cash equivalents and short-term investments as of June 30, 2023, totaled $153.6 million,...
Discussions With FDA Progressing on Potential BLA Submission for Tab-cel® With Meeting Scheduled To Resolve Remaining Topic of Comparability ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication Will Now Occur in Early November To Include the Last Patient Visits From More Th...
2023-08-04 17:35:56 ET Gainers: Atara Biotherapeutics ( ATRA ) +5% . NGM Biopharmaceuticals ( NGM ) +5% . Galera Therapeutics ( GRTX ) +4% . Ovid Therapeutics ( OVID ) +3% . Magnite ( MGNI ) +3% . Losers: Applied Material...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 20...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...